FJP Co., Ltd.’s financial results for the fiscal year ending December 2025 report operating revenue of 205 million yen, operating income of 174 million yen, net income of 118 million yen, net assets of 3,016 million yen, and total assets of 3,650 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharmaceutical Industry Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4554-20260219-01.pdf","jir_short_summary":"FJP Co., Ltd.'s financial results for the fiscal year ending December 2025 report operating revenue of 205 million yen, operating income of 174 million yen, net income of 118 million yen, net assets of 3,016 million yen, and total assets of 3,650 million yen.","jir_summary":"### Overview of FJP Co., Ltd.\u2019s Financial Results\nThis is a report on the financial results of FJP Co., Ltd. for the fiscal year ending December 2025. Operating revenue was 205 million yen with operating expenses of 31 million yen, resulting in an operating income of 174 million yen. Non-operating income totaled 42 million yen and non-operating expenses were 71 million yen, leading to an ordinary income of 146 million yen. After deducting corporate taxes and other taxes of 28 million yen, the net income was 118 million yen. The balance sheet recorded net assets of 3,016 million yen and total assets of 3,650 million yen.\n\n### Status of Shareholders and Directors\nThe major shareholder is Mr. Hirofumi Imai, holding 5,750 shares, representing a 94.26% ownership stake. The President and Representative Director is Mr. Minoru Ozawa, who concurrently serves as an outside director of our company. FJP Co., Ltd. primarily engages in the trading, management, and operation of securities and maintains personnel relationships with our company but currently has no transactional relationship.","jir_financial_highlights":"Operating Revenue: 205 million yen (Unknown)\nOperating Income: 174 million yen (Unknown)\nOrdinary Income: 146 million yen (Unknown)\nNet Income: 118 million yen (Unknown)\nNet Assets: 3,016 million yen (Unknown)\nTotal Assets: 3,650 million yen (Unknown)","jir_category":"","jir_hashtags":"#FujiPharmaceuticalIndustry, #FinancialInformation, #JapaneseStocks","jir_key_figures":"Operating Revenue: 205 million yen\nNet Income: 118 million yen\nNet Assets: 3,016 million yen","jir_meta_title":"FJP Co., Ltd. Announces Fiscal Year Ending December 2025 Financial Results | Operating Revenue 205 Million Yen, Net Income 118 Million Yen","jir_meta_description":"Fuji Pharmaceutical Industry Co., Ltd. announces the fiscal year ending December 2025 financial results of its related company, FJP Co., Ltd., detailing operating revenue of 205 million yen and net income of 118 million yen.","jir_og_title":"FJP Co., Ltd. Publishes Fiscal Year Ending December 2025 Financial Results","jir_og_description":"Fuji Pharmaceutical Industry Co., Ltd. discloses the fiscal year ending December 2025 financial information of FJP Co., Ltd., reporting operating revenue of 205 million yen and net income of 118 million yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-30250","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n